The European Association for the Study of Diabetes (EASD) has collected data, the analysis of which concludes that Levemir ® (insulin injection), a once-daily treatment for patients of diabetes (type 1 and 2), can also lead to weight loss for insulin-naïve patients with type 2 diabetes. It provides a similar blood glucose response as glargine without any important difference in daily average consumption (DACON). The costs on pharmacy, too, remain the same.